-
2023-08-15
PharmaEngine announces first patient dosed in Phase I trial of PEP07 for hematological cancers
-
2023-07-11
PharmaEngine announces EMA's acceptance of ONIVYDE®'s Type II Variation application
-
2023-06-21
PharmaEngine files post-approval change application for a new indication of ONIVYDE® to TFDA
-
2023-06-14
PharmaEngine announces Phase I clinical study of PEP07 has been approved by Taiwan Food and Drug Administration (TFDA)
-
2023-03-03
PharmaEngine announces Phase I clinical study of PEP07 has been approved by Australia HREC and acknowledged by Australia TGA
-
2023-01-25
PEP07: A novel, brain penetrant oral Chk1 inhibitor for the treatment of AML and MCL (6th Annual DDR Inhibitors Summit 2023)
-
2023-01-21
ONIVYDE® regimen (NALIRIFOX) demonstrated statistically significant improvement in overall survival in 1L PDAC (supplementary information)
-
2022-11-09
Positive topline results from Phase III NAPOLI-3 trial of ONIVYDE® regimen (NALIRIFOX) as a first-line treatment for previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)
-
2022-09-25
PharmaEngine, Inc. exercised option for a worldwide exclusive license agreement to Sentinel Oncology Limited's CHK1 inhibitor
-
2022-08-04
The results from Phase III RESILIENT trial of irinotecan liposome injection (ONIVYDE®) as a second-line monotherapy treatment for small cell lung cancer (2L SCLC)